Advertisement
CMMB vs IDYA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CMMB is a Hold and IDYA is a Buy.
CMMB in downward trend: price dove below 50-day moving average on September 28, 2026
CMMB moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend. In 38 of 40 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CMMB as a result. In 67 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The 10-day moving average for CMMB crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMMB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CMMB entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +20.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where CMMB advanced for three days, in 198 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
CMMB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.911) is normal, around the industry mean (2.973). P/E Ratio (-1.125) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. CMMB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IDYA's RSI Indicator ascends from oversold territory
The RSI Oscillator for IDYA moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 30 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on IDYA as a result. In 81 of 109 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for IDYA just turned positive on October 22, 2026. Looking at past instances where IDYA's MACD turned positive, the stock continued to rise in 40 of 49 cases over the following month. The odds of a continued upward trend are 82%.
Following a +2.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDYA advanced for three days, in 218 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
IDYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
IDYA moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IDYA crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
The Aroon Indicator for IDYA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.907) is normal, around the industry mean (2.973). P/E Ratio (-18.812) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (14.409) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating steady price growth. IDYA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 77 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
CMMB | IDYA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 43 Fair valued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 77 | |
SMR RATING 1..100 | 98 | 94 | |
PRICE GROWTH RATING 1..100 | 90 | 51 | |
P/E GROWTH RATING 1..100 | 17 | 43 | |
SEASONALITY SCORE 1..100 | 27 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IDYA's Valuation (10) in the null industry is somewhat better than the same rating for CMMB (43) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than CMMB’s over the last 12 months.
IDYA's Profit vs Risk Rating (77) in the null industry is in the same range as CMMB (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to CMMB’s over the last 12 months.
IDYA's SMR Rating (94) in the null industry is in the same range as CMMB (98) in the Biotechnology industry. This means that IDYA’s stock grew similarly to CMMB’s over the last 12 months.
IDYA's Price Growth Rating (51) in the null industry is somewhat better than the same rating for CMMB (90) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than CMMB’s over the last 12 months.
CMMB's P/E Growth Rating (17) in the Biotechnology industry is in the same range as IDYA (43) in the null industry. This means that CMMB’s stock grew similarly to IDYA’s over the last 12 months.
| CMMB | IDYA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 84% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 89% | 2 days ago 74% |
| MACD ODDS (%) | N/A | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Advances ODDS (%) | 22 days ago 84% | 2 days ago 75% |
| Declines ODDS (%) | 2 days ago 90% | 8 days ago 76% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 74% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CMMB’s FA Score shows that 1 FA rating(s) are green while IDYA’s FA Score has 1 green FA rating(s).
- CMMB’s FA Score: 1 green, 4 red.
- IDYA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CMMB’s TA Score shows that 4 TA indicator(s) are bullish while IDYA’s TA Score has 5 bullish TA indicator(s).
- CMMB’s TA Score: 4 bullish, 5 bearish.
- IDYA’s TA Score: 5 bullish, 5 bearish.
Price Growth
CMMB (@Biotechnology) experienced а -16.28% price change this week, while IDYA (@Biotechnology) price change was +6.71% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.96%. For the same industry, the average monthly price growth was -16.55%, and the average quarterly price growth was -16.97%.
Reported Earning Dates
CMMB is expected to report earnings on Mar 10, 2027.
IDYA is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Biotechnology (+0.96% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IDYA and
Correlation & Price change
A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with RNA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then RNA could also see price increases.
| Ticker / NAME | Correlation To IDYA | 1D Price Change % | ||
|---|---|---|---|---|
| IDYA | 100% | +1.83% | ||
| RNA - IDYA | 48% Loosely correlated | +2.00% | ||
| DYN - IDYA | 48% Loosely correlated | -1.87% | ||
| SLDB - IDYA | 47% Loosely correlated | -3.43% | ||
| KURA - IDYA | 46% Loosely correlated | -0.20% | ||
| XNCR - IDYA | 45% Loosely correlated | +2.70% | ||
More | ||||